Documentation and Follow-up

A useful injectable record allows another qualified clinician to reconstruct the baseline, product, preparation, placement, immediate findings, and later course. Brand name alone is not enough.

Standardize the baseline

Capture the untreated state before anesthetic, marking, manipulation, or injection changes the appearance.

Choose the baseline measurement from the defined structural or skin-quality objective rather than documenting an undefined “rejuvenation” endpoint.

Use:

consistent camera, lens, distance, height, and background
reproducible lighting and head position
frontal, oblique, and lateral views as appropriate
rest and standardized animation when movement affects the finding
removal of makeup, hair, or jewelry that obscures the area
a defined consent and storage process for clinical images

Published aesthetic guidance emphasizes consistent lighting, angles, distance, neutral positioning, and comparable views at rest and animation (photography guidance 🔗).

Record the product so it can be traced

Domain	Minimum useful detail
Identity	Brand, variant, material, presentation, local approval context
Traceability	Lot or batch, expiry, UDI where applicable, supplier pathway
Preparation	Diluent, volumes, additions, timing, mixing, final state
Treatment	Date, area, side, amount, device, documented plane and pattern
Context	Indication, off-label status, relevant prior implants
Immediate review	Appearance, symptoms, observations, deviations, response

Expert consensus recommends recording the filler name and amount, treated areas, injection pattern and technique, and retaining the batch sticker in the medical record (documentation consensus 🔗).

For a reconstituted product, also record preparation time and the source of the preparation instruction. For a ready-to-use product, document any label-permitted dilution, mixing, or addition rather than leaving the record as “used as supplied.”

Separate immediate appearance from outcome

Immediate photography can document symmetry, color, and acute findings, but it may show edema, fluid, HA, or carrier-related correction. Do not label it as the final collagen-related outcome.

Choose later review points according to the exact product, treatment objective, current IFU, and published protocol. At every review, use the same imaging conditions and record both clinician- and patient-reported findings.

Make unplanned follow-up reconstructable

For a new concern, record:

exact onset and progression
pain, tenderness, itch, warmth, erythema, color change, discharge, or systemic symptoms
visible versus palpable finding
photographs under comparable conditions
recent illness, vaccination, dental procedure, or local intervention
examination, imaging, culture, referral, and treatment chronology
product and batch information

The nodule and delayed-reaction framework provides a descriptive starting point without treating every mass as the same diagnosis.

Close the safety loop

Document patient contact attempts, escalation advice, referrals, specialist handover, outcome, and follow-up plan. Serious or unexpected events may also require notification to the manufacturer, distributor, insurer, regulator, or institutional safety system according to local rules.

In the United States, the FDA explains mandatory reporting duties for manufacturers, importers, and defined user facilities, and encourages voluntary reporting by health professionals through MedWatch (FDA medical-device reporting 🔗).

Follow-up output

A complete episode links baseline, consent, treatment, planned review, unplanned contacts, adverse-event evaluation, and final disposition. This continuity is particularly important for products whose clinical response or complications can emerge after the immediate post-treatment period.